Dr Scarlett brings nearly 30 years of experience in drug development and commercialization to his new role. Susan Molineaux, who founded Proteolix in 2003, will transition from her position as CEO to serve as the company’s chief scientific officer.
Most recently, Dr Scarlett served as the CEO of Tercica, a biotechnology company. Dr Scarlett has graduated with honors from the University of Chicago’s Pritzker School of Medicine.
Ms Molineaux said: “I welcome Dr Scarlett, whose extensive clinical and commercial experience will serve as an important asset to the company as carfilzomib advances through late-stage trials.”